JP2021534769A5 - - Google Patents

Info

Publication number
JP2021534769A5
JP2021534769A5 JP2021510191A JP2021510191A JP2021534769A5 JP 2021534769 A5 JP2021534769 A5 JP 2021534769A5 JP 2021510191 A JP2021510191 A JP 2021510191A JP 2021510191 A JP2021510191 A JP 2021510191A JP 2021534769 A5 JP2021534769 A5 JP 2021534769A5
Authority
JP
Japan
Prior art keywords
cancer
polypeptide
cell
antigen
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534769A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048921 external-priority patent/WO2020047326A2/en
Publication of JP2021534769A publication Critical patent/JP2021534769A/ja
Publication of JP2021534769A5 publication Critical patent/JP2021534769A5/ja
Pending legal-status Critical Current

Links

JP2021510191A 2018-08-31 2019-08-29 デコイポリペプチド Pending JP2021534769A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725977P 2018-08-31 2018-08-31
US62/725,977 2018-08-31
PCT/US2019/048921 WO2020047326A2 (en) 2018-08-31 2019-08-29 Decoy polypeptides

Publications (2)

Publication Number Publication Date
JP2021534769A JP2021534769A (ja) 2021-12-16
JP2021534769A5 true JP2021534769A5 (https=) 2022-09-06

Family

ID=67997686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510191A Pending JP2021534769A (ja) 2018-08-31 2019-08-29 デコイポリペプチド

Country Status (5)

Country Link
US (1) US20210347848A1 (https=)
EP (1) EP3843772A2 (https=)
JP (1) JP2021534769A (https=)
MA (1) MA53493A (https=)
WO (1) WO2020047326A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
CN121243368A (zh) * 2019-11-27 2026-01-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
KR20230018475A (ko) * 2020-06-01 2023-02-07 알렉소 온콜로지 인크. 암 치료용 저메틸화제를 포함하는 병용 요법
US20220196651A1 (en) * 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
WO2025222106A1 (en) * 2024-04-18 2025-10-23 Aktis Oncology, Inc. Decoy miniproteins, compositions, & methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US20030118997A1 (en) * 2001-08-10 2003-06-26 Genset, S.A. Human cDNAs and proteins and uses thereof
US7074891B2 (en) * 2003-02-07 2006-07-11 Posco Leukocyte stimulating peptides
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
CA2647524C (en) 2006-04-05 2019-11-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AR066240A1 (es) * 2007-04-23 2009-08-05 Wyeth Corp Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2010070047A1 (en) * 2008-12-19 2010-06-24 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
HRP20150553T1 (hr) * 2009-05-15 2015-08-28 University Health Network Sastavi i metode za lijeäśenje hematoloških maligniteta ciljajuä†i sirp - cd47 interakciju
EP2699596A4 (en) * 2011-04-22 2015-01-14 Emergent Product Dev Seattle PROSTATE-SPECIFIC MEMBRANE-BINDING PROTEINS AND COMPOSITIONS AND METHOD THEREFOR
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
PL3575326T3 (pl) * 2012-12-17 2022-07-11 Pf Argentum Ip Holdings Llc Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc
WO2016023040A1 (en) * 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
CN114425077A (zh) * 2015-05-18 2022-05-03 起源生物医药公司 Sirp多肽组合物和使用方法
EA034582B1 (ru) * 2015-08-07 2020-02-21 АЭлЭкс ОНКОЛОДЖИ ИНК. Конструкции варианта sirp-альфа и их применение
AU2016304794B2 (en) * 2015-08-07 2021-07-15 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
WO2018118887A1 (en) * 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
CN116239698A (zh) * 2019-03-06 2023-06-09 江苏恒瑞医药股份有限公司 双功能融合蛋白及其医药用途

Similar Documents

Publication Publication Date Title
JP2021534769A5 (https=)
JP7487112B2 (ja) Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用
US12384850B2 (en) Guidance and navigation control proteins and method of making and using thereof
JP2025118616A (ja) 抗ｐｄ－１－抗ｖｅｇｆａ二重特異性抗体、その医薬組成物および使用
JP2025078629A5 (https=)
JP2023519974A5 (https=)
IL268836B1 (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
IL271325B1 (en) Guidance and navigation control proteins and method of making and using thereof
JP2019500892A5 (https=)
RU2018145961A (ru) Комбинированная терапия
TWI874613B (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
CA2963696A1 (en) Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
RU2018105963A (ru) Антитело против глипикана-3 и его применение
JP2021513961A5 (https=)
CN115232209A (zh) 靶向gprc5d的抗体及其用途
RU2020122822A (ru) Биспецифичные связывающие cd16 молекулы и их применение при лечении заболеваний
JP2021505637A5 (https=)
US20250236864A1 (en) CAR LIBRARY AND scFv MANUFACTURING METHOD
JP2020525432A (ja) 非対称ヘテロ二量体ＦＣ−ＳＣＦＶ融合抗ＧＬＯＢＯ Ｈおよび抗ＣＤ３二重特異的抗体およびがん療法（ｃａｎｅｒ ｔｈｅｒａｐｙ）におけるその使用
CN115298219A (zh) 多特异性抗体在治疗数个疾病方面的用途
CA3221115A1 (en) Treatment of pd-l1 negative or low expressing cancer with anti-icos antibodies
EP4508072A1 (en) T-cell engaging polypeptides and methods of use thereof
RU2020126486A (ru) Вариантные связывающие cd3 домены и их применение в комбинированной терапии при лечении заболеваний
RU2002128721A (ru) Многофункциональные полипептиды, содержащие сайт связывания с эпитопом nkg2d-рецепторного комплекса
NZ740365A (en) Cd3 binding polypeptides